Meloxicam

Mechanism

Ketorolac outweighs other NSAIDs in antiplatelet and ulcerogenic effect. Its label places treatment with aspirin or other NSAIDs, selective COX-2 inhibitors included, among the contraindications, and the interactions section states it must not be used with other NSAIDs because of the increased rate of serious class adverse effects: gastrointestinal bleeding and perforation, renal injury, and bleeding from platelet inhibition. Analgesia does not improve when the second drug is added, since the target is the same enzyme family – cyclooxygenase.

Symptoms

Black or tarry stools, coffee-ground vomit, epigastric pain, sudden weakness and pallor from anaemia. Falling urine output and swelling as a sign of renal injury. In older people and those with a history of ulcer the picture may begin with the bleed itself, without preceding pain.

Management

The combination is taken apart: one NSAID remains. For severe pain that is usually ketorolac in a short course within the label limit, with the rest of the analgesia covered by paracetamol, metamizole or an opioid. Gastroprotection with a proton pump inhibitor does not lift the contraindication. After a ketorolac dose, another NSAID is not added until its action ends, not merely until the next scheduled dose.

Mechanism

Meloxicam and aspirin are both NSAIDs. Together they damage the stomach and gut lining more, and the risk of ulcers and bleeding rises through a synergistic effect (meloxicam and aspirin 100 mg SmPCs). In a clinical study cited in the US meloxicam label (FDA), an NSAID plus aspirin caused significantly more gastrointestinal adverse reactions than the NSAID alone. Aspirin also inhibits platelet aggregation for several days after a dose (aspirin 100 mg SmPC).

Symptoms

Gum bleeding, epistaxis, bruising without trauma, black or tarry stools. Severe cases: GI bleeding.

Management

The meloxicam SmPC does not recommend combining it with aspirin at 500 mg or more per dose or 3 g or more a day, and the aspirin 100 mg SmPC advises avoiding NSAIDs with aspirin whenever possible (meloxicam and aspirin 100 mg SmPCs). The FDA does not generally recommend meloxicam with either low-dose or analgesic-dose aspirin because of bleeding risk, and notes that meloxicam is not a substitute for low-dose aspirin for cardiovascular protection (US meloxicam label). If meloxicam is still needed with low-dose aspirin, consider gastroprotection with misoprostol or a proton pump inhibitor (meloxicam SmPC). Warn the patient in advance about signs of bleeding: black stools, vomiting blood, abdominal pain, weakness, dizziness, cold sweat. If they appear, the patient stops the medicines and seeks medical care at once (aspirin 100 mg SmPC).

Mechanism

Apixaban is a direct factor Xa inhibitor; meloxicam blocks platelet function and injures the GI mucosa. Additive GI bleeding risk increases 2- to 3-fold.

Symptoms

Black or tarry stools (melena), vomiting blood or coffee-ground material, epigastric pain. Risk multiplies in older patients and with prior peptic ulcer disease.

Management

Avoid prolonged combination. If meloxicam is needed for a short course, use the minimum effective dose for 5–7 days with pantoprazole cover. For chronic analgesia: paracetamol or celecoxib.

Mechanism

Similar to iopromide + naproxen. Contrast and NSAID – additive nephrotoxicity.

Symptoms

Reduced urine output, rising creatinine and potassium, oedema. Symptoms appear earlier in older patients and chronic kidney disease.

Management

Stop meloxicam 48 hours before planned contrast and resume 48 hours after with stable renal function. Alternative analgesic: paracetamol. Provide contrast nephroprotection with adequate hydration.

Mechanism

NSAIDs reduce renal methotrexate clearance. At high oncologic doses: myelosuppression and mucositis. At low rheumatologic doses, risk is smaller but monitoring is needed.

Symptoms

Stomatitis, diarrhoea, falling leukocyte, platelet, and erythrocyte counts. Severe cases: fatal pancytopenia, nephrotoxicity.

Management

At oncologic methotrexate doses, the combination is not prescribed. At low rheumatologic doses, meloxicam is acceptable for a short course with blood count and creatinine monitoring every 1–3 months.

Mechanism

Direct oral anticoagulant (rivaroxaban) + NSAID (meloxicam) – additive GI bleeding risk via combined anticoagulation, mucosal injury, and platelet dysfunction.

Symptoms

Black or tarry stools, vomiting blood, epigastric pain. Risk multiplies in older patients and with prior peptic ulcer disease.

Management

Avoid prolonged combination. If meloxicam is needed for a short course, use the minimum effective dose for 5–7 days under pantoprazole cover. For chronic analgesia: paracetamol or celecoxib.

Mechanism

NSAID (meloxicam) + nephrotoxic calcineurin inhibitor (tacrolimus) – additive acute kidney injury risk in transplant patients.

Symptoms

Reduced urine output, rising creatinine and potassium, oedema. Symptoms appear earlier in older patients and chronic kidney disease.

Management

Avoid prolonged combination. For post-transplant analgesia: paracetamol (up to 2 g/day) or a short opioid course. For neuropathic pain: gabapentin or pregabalin.

Mechanism

Meloxicam (preferential COX-2 NSAID) inhibits platelet aggregation less than non-selective NSAIDs but still injures the gastric mucosa. On warfarin, bleeding risk rises moderately.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.

Management

When unavoidable, use the minimum effective meloxicam dose for short courses under pantoprazole cover. Check INR at 1 week. For chronic needs, celecoxib or paracetamol are preferable.

Mechanism

NSAIDs antagonise amlodipine's antihypertensive effect via renal prostaglandin-dependent sodium regulation suppression.

Symptoms

Gradual blood pressure rise 1–2 weeks after starting meloxicam. In chronic kidney disease: fluid retention and oedema risk.

Management

For short meloxicam courses (5–7 days), monitor blood pressure. For chronic analgesia: switch to paracetamol or celecoxib (with PPI cover).

Mechanism

NSAIDs weaken the antihypertensive effect of beta-blockers. Meloxicam is less ulcerogenic than non-selective NSAIDs (preferential COX-2 activity), but the renal effect persists.

Symptoms

Gradual blood pressure rise 1–2 weeks after starting the NSAID. In chronic kidney disease: risk of fluid retention and oedema.

Management

For short meloxicam courses (5–7 days), monitor blood pressure. For chronic analgesia: switch to paracetamol or celecoxib (with PPI cover).

Mechanism

The liver breaks down meloxicam mainly through the enzyme CYP2C9, with a smaller contribution from the enzyme CYP3A4. Itraconazole strongly inhibits CYP3A4, yet it lowers meloxicam levels. In a study with meloxicam 15 mg, peak concentration fell by 64% and the area under the curve by 37%. The labels do not explain why. The risk of the combination is that meloxicam may work less well.

Symptoms

Meloxicam may relieve pain and inflammation less well. In osteoarthritis flares, rheumatoid arthritis or ankylosing spondylitis, pain and stiffness in the joints or spine return or get worse. Meloxicam levels fall with this pair, so the labels describe no meloxicam overdose from it.

Management

Use meloxicam cautiously alongside itraconazole. Check whether its effect has weakened and adjust the dose if needed (itraconazole label, Spanish Agency of Medicines and Medical Devices, AEMPS). A higher meloxicam dose may be necessary (itraconazole label, US Food and Drug Administration, FDA). The meloxicam dose limit stays the same: no more than 15 mg a day, and no more than 7.5 mg a day in patients on dialysis with severe kidney failure (meloxicam label, AEMPS). Give meloxicam at the lowest effective dose for the shortest time, and regularly review whether it is still needed and how well it works (meloxicam label, AEMPS). If the meloxicam dose was raised during the itraconazole course, review it in the same way after itraconazole is stopped. Itraconazole takes 7–14 days to leave the blood (itraconazole label, AEMPS).